Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis

被引:18
|
作者
Urshansky, Nataly
Mausner-Fainberg, Karin [2 ]
Auriel, Eitan [2 ]
Regev, Keren
Bornstein, Natan M. [2 ,3 ]
Karni, Arnon [1 ,2 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Neurol, Neuroimmunol Lab & Clin, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Dept Neurol, Stroke Unit, IL-64239 Tel Aviv, Israel
关键词
Noggin; Multiple sclerosis; T cells; Neurogenesis; OLIGODENDROCYTE PRECURSOR CELLS; REGULATORY T-CELLS; SPINAL-CORD-INJURY; DENDRITIC CELLS; NEUROTROPHIC FACTOR; STEM/PROGENITOR CELLS; FUNCTIONAL RECOVERY; GLATIRAMER ACETATE; CNS REMYELINATION; BRAIN-LESIONS;
D O I
10.1016/j.jneuroim.2010.10.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple sclerosis (MS) plaques are characterized by neurodegeneration, astrogliolis, the presence of immature oligodendrocytes and infiltrating immune cells. Recent studies revealed a putative role for noggin in both neurogenesis and oligodenrocytes development. In order to study the potential of peripheral immune cells to contribute to neurogenesis in MS, we studied the mRNA expression, protein secretion and regulation profile of noggin in peripheral blood mononuclear cells (PBMCs) of untreated patients with relapsing-remitting MS (RR-MS), interferon-beta (IFN-beta) treated RR-MS patients compared to matched healthy controls (HC). Basal levels of noggin mRNA expression, determined by quantitative real-time PCR were lower in untreated patients than in HC. No differences were found between untreated patients and IFN-beta treated patients. Similarly, the secreted levels of noggin, detected in 24 h PBMCs supernatants by ELISA, were decreased in untreated RR-MS patients than in HC. Again no significant differences were found between untreated patients and IFN-beta treated patients. Stimulation with anti-CD3/CD28 mAbs increased noggin mRNA expression in untreated patients but not in HC. However, noggin mRNA levels in untreated patients PBMCs stimulated with anti-CD3/CD28 did not reach noggin levels in unstimulated PBMCs of HC. Purification of monocytes (CD14+) and T cells (CD3+ cells) by magnet-activated cell separation has demonstrated that noggin mRNA is predominantly expressed in CD3+ cells in both HC and in RR-MS patients. This pattern also appeared in protein level of noggin, tested by Western blot. The incubation of the PBMCs with TNF-alpha increased the expression of noggin only in HC group. In conclusion, T cells possess the potential to participate in the induction of neurogeneration by the production of noggin. This potential seems to be defective in immune cells of RR-MS patients as there is reduced mRNA expression and protein secretion levels of noggin, insufficient stimulatory effect of CD3/CD28 stimulation and unresponsiveness to TNF-alpha in these patients PBMCs. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:171 / 178
页数:8
相关论文
共 50 条
  • [31] Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis
    Cocco, E.
    Marchi, P.
    Sardu, C.
    Russo, P.
    Paolillo, A.
    Mascia, M. G.
    Solla, M.
    Frau, J.
    Lorefice, L.
    Massole, S.
    Floris, G.
    Marrosu, M. G.
    MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (08) : 975 - 980
  • [32] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [33] Sexual dysfunction in female patients with relapsing-remitting multiple sclerosis
    Bartnik, Pawel
    Wielgos, Aleksandra
    Kacperczyk, Joanna
    Pisarz, Katarzyna
    Szymusik, Iwona
    Podlecka-Pietowska, Aleksandra
    Zakrzewska-Pniewska, Beata
    Wielgos, Miroslaw
    BRAIN AND BEHAVIOR, 2017, 7 (06):
  • [34] B Cells as a Therapeutic Target for IFN-β in Relapsing-Remitting Multiple Sclerosis
    Ramgolam, Vinod S.
    Sha, Yonggang
    Marcus, Karen L.
    Choudhary, Neelima
    Troiani, Luigi
    Chopra, Manisha
    Markovic-Plese, Silva
    JOURNAL OF IMMUNOLOGY, 2011, 186 (07): : 4518 - 4526
  • [35] Facial emotion recognition in patients with relapsing-remitting multiple sclerosis
    Fereydouni, Soodabe
    Hadianfard, Habib
    Ashjazadeh, Nahid
    NEUROLOGY ASIA, 2019, 24 (04) : 327 - 332
  • [36] Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis
    Kashani, Nicole
    Kelland, Eve E.
    Vajdi, Borna
    Anderson, Lauren M.
    Gilmore, Wendy
    Lund, Brett T.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [37] Quality of life in relapsing-remitting multiple sclerosis
    Dayapoglu, Nuray
    Tan, Mehtap
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2011, 27 (01) : 133 - 137
  • [38] Immunomonitoring measures in relapsing-remitting multiple sclerosis
    Matsui, M
    Araya, S
    Wang, HY
    Matsushima, K
    Saida, T
    JOURNAL OF NEUROIMMUNOLOGY, 2004, 148 (1-2) : 192 - 199
  • [39] Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis
    M. C. Buscarinu
    S. Romano
    R. Mechelli
    R. Pizzolato Umeton
    M. Ferraldeschi
    A. Fornasiero
    R. Reniè
    B. Cerasoli
    E. Morena
    C. Romano
    N. D. Loizzo
    R. Umeton
    M. Salvetti
    G. Ristori
    Neurotherapeutics, 2018, 15 : 68 - 74
  • [40] Fatigue in multiple sclerosis relapsing-remitting form
    Mendes, MF
    Tilbery, CP
    Balsimelli, S
    Felipe, E
    Moreira, MA
    Barao-Cruz, AM
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2000, 58 (2B) : 471 - 475